Povsic Thomas J, Zavodni Katherine L, Kelly Francine L, Zhu Shoukang, Goldschmidt-Clermont Pascal J, Dong Chunming, Peterson Eric D
Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA.
J Am Coll Cardiol. 2007 Dec 4;50(23):2243-8. doi: 10.1016/j.jacc.2007.08.033. Epub 2007 Nov 19.
Our objective was to develop and assess a novel endogenous progenitor cell (EPC) assay based on aldehyde dehydrogenase (ALDH) activity, and to define the relationship of ALDH-bright (ALDH(br)) cells with previously defined EPCs, patient age, and extent of coronary artery disease.
Accurate assessment of circulating EPCs is of significant interest, yet current assays have limitations. Progenitor cells display high levels of ALDH activity. An assay based on ALDH activity may offer a simple means for enumerating EPCs.
We simultaneously determined the numbers of EPCs based on ALDH activity and cell surface expression of CD133, CD34, and vascular endothelial growth factor receptor-2 in 110 patients undergoing cardiac catheterization. We assessed the reproducibility of these estimates, correlation among EPC assays, and the association of ALDH(br) numbers with age and disease severity.
Aldehyde dehydrogenase-bright cells were easily identified in nonmobilized peripheral blood with median and mean frequencies of 0.041% and 0.074%, respectively. Aldehyde dehydrogenase-bright cells expressed CD34 or CD133 cell surface markers (57.0% and 27.1%, respectively), correlated closely with CD133+CD34+ cells (r = 0.72; p < 0.001), and differentiated into endothelial cells with greater efficiency than CD133+CD34+ cells. Aldehyde dehydrogenase-bright cell numbers were inversely associated with patient age and coronary disease severity.
Aldehyde dehydrogenase activity represents a novel simplified method for quantifying EPCs. The correlation of ALDH(br) cells with clinical factors and outcomes warrants further study.
我们的目标是开发并评估一种基于醛脱氢酶（ALDH）活性的新型内源性祖细胞（EPC）检测方法，并确定ALDH高表达（ALDH(br)）细胞与先前定义的EPC、患者年龄以及冠状动脉疾病程度之间的关系。
循环EPC的准确评估备受关注，但目前的检测方法存在局限性。祖细胞显示出高水平的ALDH活性。基于ALDH活性的检测方法可能为EPC计数提供一种简单手段。
我们在110例接受心导管检查的患者中，同时基于ALDH活性以及CD133、CD34和血管内皮生长因子受体-2的细胞表面表达来确定EPC的数量。我们评估了这些估计值的可重复性、EPC检测方法之间的相关性，以及ALDH(br)细胞数量与年龄和疾病严重程度的关联。
在未动员的外周血中很容易识别出醛脱氢酶高表达细胞，其频率中位数和均值分别为0.041%和0.074%。醛脱氢酶高表达细胞表达CD34或CD133细胞表面标志物（分别为57.0%和27.1%），与CD133+CD34+细胞密切相关（r = 0.72；p < 0.001），并且比CD133+CD34+细胞更有效地分化为内皮细胞。醛脱氢酶高表达细胞数量与患者年龄和冠状动脉疾病严重程度呈负相关。
醛脱氢酶活性代表了一种用于量化EPC的新型简化方法。ALDH(br)细胞与临床因素和结果之间的相关性值得进一步研究。
